Is there a cloud in the silver lining for imatinib?

Paterson, S.C., Smith, K.D., Holyoake, T.L. and Jorgensen, H.G. (2003) Is there a cloud in the silver lining for imatinib? British Journal of Cancer, 88(7), pp. 983-987. (doi: 10.1038/sj.bjc.6600828)

Full text not currently available from Enlighten.


Imatinib mesylate (GleevecĀ® or GlivecĀ®), a small molecule tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia, has been said to herald the dawn of a new er-a of rationally designed, molecularly targeted oncotherapy. Lurking on the same new horizon, however, is the age-old spectre of drug resistance. This review sets the intoxicating clinical perspective against the more sobering laboratory evidence of such divergent mechanisms of imatinib resistance as gene amplification and stem cell quiescence. Polychemotherapy has already been considered to combat resistance, but a more innovative, as yet unformulated, approach may be advocated.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Jorgensen, Dr Heather
Authors: Paterson, S.C., Smith, K.D., Holyoake, T.L., and Jorgensen, H.G.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:British Journal of Cancer

University Staff: Request a correction | Enlighten Editors: Update this record